How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

361 results for

bell's palsy guideline

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Aflunov

the “Guideline on dossier structure and content of MAA for influenza vaccines derived from strains with a pandemic potential and intended for use before the pandemic is declared” (EMEA/CHMP/VWP/263499/2006). The pre-pandemic vaccine AFLUNOV is identical to the H5N1 pandemic mock-up vaccine, previously identified as Focetria, already approved by EMA (May 2007, Commission decision) for pandemic use. Currently the name Focetria identifies the actual H1N1 pandemic vaccine and the name Foclivia has been (...) batches of NIBRG-14 H5N1 Monovalent Pooled harvest. The key stability-indicating parameter are the HA content and purity, measured with the same methods and acceptance limits used at release. The data are consistent with the proposed shelf-life of 24 months for the active substance when stored at 2-8°C. In accordance with EU GMP guidelines 1 , any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA. 2.2.3. Finished Medicinal Product

2011 European Medicines Agency - EPARs

142. Arepanrix

of Pandemrix to A/California/07/2009 (H1N1)v like strain (A-179A). The strain used has been officially recommended by WHO and CHMP for the manufacture of vaccines during the current pandemic. 1 Guideline on Submission of Marketing Authorisation Applications for Pandemic Influenza Vaccines through the Centralised Procedure (CPMP/VEG/4986/03). Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisations Application (CPMP/VEG/4717/03). Medicinal product no longer (...) of resolubilisation of the aggregates. Overall, the information presented in Modules 2.3 and 3 was considered in accordance with the above- mentioned guidelines and therefore acceptable. Medicinal product no longer authorisedPage 12 of 87 2.3 Non-clinical aspects Introduction Preclinical development of Arepanrix was generally in agreement with current guidelines. The antigen is produced in hen’s eggs using the same process as that is applied to the applicant’s own FluLaval brand of seasonal influenza vaccine

2011 European Medicines Agency - EPARs

143. Pumarix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

(core pandemic dossier) for Pumarix in line with the above mentioned guidelines. Pumarix is a split virion inactivated influenza vaccine, containing the mock-up strain H5N1 derived by reverse genetics from the avian influenza virus A/Indonesia/05/2005 (H5N1) The final formulation contains 3.75 µg haemagglutinin (HA) per 0.5 ml dose adjuvanted by AS03. Pumarix is indicated for prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used (...) to introduce the WHO/EU recommended strain, prepared from the influenza virus causing the pandemic, prior to use of Pumarix in a pandemic. Pumarix is not indicated for prophylactic use during the prepandemic period. Using immune parameters to predict protection Influenza virus infection elicits host production of antibody against several viral components but the major antigens are the haemagglutinin and neuraminidase molecules. Antibody to haemagglutinin 1 Guideline on Submission of Marketing Authorisation

2011 European Medicines Agency - EPARs

144. Diagnosis and Treatment of Peripheral Artery Diseases

Diagnosis and Treatment of Peripheral Artery Diseases ESC GUIDELINES ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC) Endorsed by: the European Stroke Organisation (ESO) Authors/Task Force Members: Michal Tendera (...) ), Horst Sievert (Germany), Marc van Sambeek (The Netherlands), Thomas Zeller (Germany). ESC Committee for Practice Guidelines (CPG): Jeroen Bax (CPG Chairperson) (The Netherlands), Angelo Auricchio (Switzerland), Helmut Baumgartner (Germany), Claudio Ceconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (The Netherlands), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril

2011 European Society of Cardiology

145. Family Practice Notebook Updates 2016

Do not treat with a single drug regimen until is excluded by history, In suspected , mask patient in negative ariflow room and induce for AFB x3 samples has not changed substantially in 10 years, but multi-drug resistance guidelines are lacking (er, procedure, fen) Quick central access without Seldinger technique (id, std) Syphilis has increased 3-4 fold in the U.S. since 2000 (now at 20,000 cases per year) is typically treated with G (or , ) for primary and secondry Avoid in due to resistance (...) Gradually developed wbc to 3.5k, hgb from 13 to 12 to 11 over 1 week of serial visits for s demonstrated RBC inclusion bodies consistent with Updated to include In failed airway, may temporize in infants and young children for 20-25 min Covers reversal of specific s (e.g. DIC, TTP, disease, renal disease, s) or (id, immunize, ) Very low efficacy in U.S. as of 2016 (as low as 3%) and will not be used in U.S. per ACIP guidelines (endo, pharm, dm) For all its mediocre activity on lowering and adverse

2017 FP Notebook

146. Humenza - pandemic influenza vaccine (H1N1, split virion, inactivated, adjuvanted)

vaccine since these data would be considered supportive for the candidate H1N1v/AF03 vaccine. General comments on compliance with GMP, GLP, GCP The clinical trials were performed in accordance with the quality standards of the International Conference on Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and reflected the requirements of the EMEA guidance. 2.2 Quality aspects Introduction The A/H1N1 Pandemic Influenza Vaccine is indicated for prophylaxis of influenza in an officially (...) of the stainless steel containers or polypropylene containers used to store MVB antigen. The container/closure system is identical to that used for the MVB storage of season influenza vaccine. Evidence of compliance with CPMP/QWP/4359/03 (Guideline on plastic immediate packaging materials) has been provided with representative certificates of analysis demonstrating compliance with specifications. ? Stability Medicinal product no longer authorised EMA/117926/2010 Page 8/49 The Applicant provided information

2010 European Medicines Agency - EPARs

147. Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics

the start of the H5N1 outbreaks in mid- 2003 until 24 September 2009, 442 individuals have been infected with laboratory-confirmed avian H5N1 influenza, 262 of whom died (http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009 _09_24/en/index.html). This MAA took into account the “Guideline on dossier structure and content of MAA for influenza vaccines derived from strains with a pandemic potential and intended for use before the pandemic is declared” (EMEA/CHMP/VWP/263499/2006). The pre (...) . The key stability-indicating parameter are the HA content and purity, measured with the same methods and acceptance limits used at release. The data are consistent with the proposed shelf-life of 24 months for the active substance when stored at 2-8°C. In accordance with EU GMP guidelines 1 , any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA. 2.2.3. Finished Medicinal Product Prepandemic influenza vaccine (H5N1) (surface antigen

2010 European Medicines Agency - EPARs

148. Oral corticosteroid prescribing habits of Canadian Otolaryngologist-Head and Neck Surgeons Full Text available with Trip Pro

and tapering of OCSs were assessed in acute rhino-sinusitis (ARS), chronic rhino-sinusitis with (CRSwP) and without polyps (CRSsP), sudden sensori-neural hearing loss (SSNHL), and idiopathic facial nerve/Bell's palsy (IFN). Participants were asked to complete for conditions treated and results were compared with current guidelines. Development of prescribing habits and observed complications were also explored.124 surveys (18%) were completed. In CRSwP (N = 98), the median dose was 50 mg (Range: 10-100 mg

2016 Journal of Otolaryngology - Head & Neck Surgery

149. Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation Patient must not have active tuberculosis Patients must not have active hepatitis B (chronic or acute) or active hepatitis C infection Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg (...) studies Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines As a part of the oncology patient enrollment network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system Contacts and Locations Go to Information from

2016 Clinical Trials

150. Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

colitis, or other symptomatic lower GI conditions that might predispose to perforations History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener?s granulomatosis, Sjogren?s syndrome, Bell?s palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; Note: patients with a history of autoimmune (...) to randomization; hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula or a 24 hour urine obtained =< 7 days prior to randomization The following laboratory values obtained =< 14 days prior to randomization Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 X ULN if not anticoagulated; within local institutional guidelines per

2016 Clinical Trials

151. Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however, Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible Patients with controlled type 1 diabetes mellitus on a stable insulin (...) : All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer Tumor determined to be mismatch-repair deficient (dMMR

2016 Clinical Trials

152. Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

) is negative for HCV ribonucleic acid (RNA) History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid (...) in the invasive component of the tumor (provided the patient is being treated as triple negative breast cancer) Human epidermal growth factor receptor 2 (HER2) negative by fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) staining 0 or 1+ according to National Comprehensive Cancer Network (NCCN) guidelines Clinical stage T2-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging Eligible for neoadjuvant chemotherapy No prior therapy

2016 Clinical Trials

153. Peripheral facial paralysis

Peripheral facial paralysis © 2010, Dutch College of General Practitioners www.nhg.org august 2010 Peripheral facial paralysis: complete or partial unilateral paralysis of the facial musculature resulting from a functional disorder of the nervus facialis. In case of complete failure of the facial nerve, the facial musculature is completely paralysed, with the corner of the mouth hanging and inability to close the eye on the affected side. Idiopathic peripheral facial paralysis (IPFP, Bell palsy (...) for the presence of blisters; ? the ear for signs of otitis media, otitis externa, the presence of a tumour or cholesteatoma; ? the mouth, tonsil region and neck for the presence of a tumour; ? the ability to close the eyelids and any conjunctival redness. Make the diagnosis of IPFP if the facial paralysis is peripheral, occurred within a short time and if there are no signs of an underlying cause. PERIPHERAL FACIAL PARALYSIS NHG GUIDELINE (summary) M93 TERMS History Physical examination Evaluation DIAGNOSTIC

2010 Dutch College of General Practitioners (NHG)

154. Management of Women with Obesity in Pregnancy

Management of Women with Obesity in Pregnancy CMACE/RCOG Joint Guideline Management of Women with Obesity in Pregnancy March 2010 Centre for Maternal and Child Enquiries Improving the health of mothers, babies and children This guideline was produced on behalf of the Centre for Maternal and Child Enquiries and the Royal College of Obstetricians and Gynaecologists by: J Modder MRCOG, CMACE and KJ Fitzsimons Ph.D, CMACE and reviewed by the RCOG Guidelines Committee. The final version (...) is the responsibility of both CMACE and the Guidelines Committee of the RCOG. Updates of this guideline will be the responsibility of the Guidelines Committee of the RCOG. DISCLAIMERS CMACE ACKNOWLEDGEMENTS AND DISCLAIMER This work was undertaken by the Centre for Maternal and Child Enquiries (CMACE) as part of the CEMACH programme. The work was funded by the National Patient Safety Agency; the Department of Health, Social Services and Public Safety of Northern Ireland; NHS Quality Improvement Scotland (NHS QIS

2010 Royal College of Obstetricians and Gynaecologists

155. Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

in Chinese hamster ovary cells or any component of the MPDL3280A formulation Patients with prior allogeneic stem cell or solid organ transplantation History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis History (...) and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of study drug. Exclusion Criteria: Evidence of bilateral breast cancer or metastatic disease (M1) Cases with an histology different from invasive ductal NOS of high proliferation or grade Patients with HER2-positive disease according to ASCO/CAP guidelines 2013 Pregnant or lactating women

2015 Clinical Trials

156. Pancreatic Cancer, Childhood

for specific information about supportive care for children and adolescents with cancer.) Guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer have been outlined by the American Academy of Pediatrics.[ ] At these pediatric cancer centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical trials (...) al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004. Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64

2012 PDQ - NCI's Comprehensive Cancer Database

157. Oral Cancer, Childhood

for specific information about supportive care for children and adolescents with cancer.) Guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer have been outlined by the American Academy of Pediatrics.[ ] At these pediatric cancer centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical trials (...) al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004. Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64

2012 PDQ - NCI's Comprehensive Cancer Database

158. Ovarian Cancer, Childhood

for specific information about supportive care for children and adolescents with cancer.) Guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer have been outlined by the American Academy of Pediatrics.[ ] At these pediatric cancer centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical trials (...) al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004. Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64

2012 PDQ - NCI's Comprehensive Cancer Database

159. Nasopharyngeal Cancer, Childhood

summaries for specific information about supportive care for children and adolescents with cancer.) Guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer have been outlined by the American Academy of Pediatrics.[ ] At these pediatric cancer centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical (...) al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004. Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64

2012 PDQ - NCI's Comprehensive Cancer Database

160. Testicular Cancer, Childhood

for specific information about supportive care for children and adolescents with cancer.) Guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer have been outlined by the American Academy of Pediatrics.[ ] At these pediatric cancer centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical trials (...) al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004. Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64

2012 PDQ - NCI's Comprehensive Cancer Database

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>